<DOC>
	<DOCNO>NCT00113048</DOCNO>
	<brief_summary>This phase I study involve escalate dos CAMPATH goal dose cohort tolerate . The CAMPATH goal dose administer patient subcutaneously ( SQ ) 3 time per week 12 week .</brief_summary>
	<brief_title>Subcutaneously Administered CAMPATH CD52 Expressing Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Patients relapse refractory hematologic malignancy . The anticipated patient population patient chronic lymphocytic leukemia ( CLL ) , nonHodgkin 's lymphoma myeloma Patients history hematologic malignancy previously show flow cytometry immunophenotyping analysis express CD52 Any chemotherapy , major surgery irradiation must complete least four ( 4 ) week enrollment study ( 6 week mitomycinC nitrosourea ) Patients recover acute side effect due prior therapy Life expectancy &gt; 3 month World Health Organization ( WHO ) Performance Status 02 18 year age old Adequate organ function define protocol Prior therapy CAMPATH Use investigational agent within two ( 2 ) week prior study enrollment History anaphylaxis follow exposure humanize monoclonal antibody Known human immunodeficiency virus ( HIV ) positive Prior autologous bone marrow stem cell transplant within six ( 6 ) month study entry A history prior allogenic bone marrow transplant organ transplant Known , symptomatic central nervous system ( CNS ) involvement lymphoma Pregnant lactate woman Uncontrolled intercurrent illness include , limited , ongoing active infection ( exclude skin infection , low urinary tract infection , oral infection ) , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>CD52 Expressing Hematologic Malignancies</keyword>
</DOC>